Trial Profile
A retrospective study to compare Imatinib vs. Dasatinib for outcomes after allogeneic stem cell transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association